+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)

Pfizer

Primary Area of Interest:

• Oncology – Hematology – Multiple Myeloma

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on increasing healthcare professional understanding and competency in the use and management of BCMA BsAbs for the treatment of Relapsed/Refractory Multiple Myeloma, and may address one or more of the following areas:

• Sharing successful practice models (inclusive of both intra- and inter- practice models) for BCMA BsAb implementation including outpatient step-up dosing, identifying challenges and presenting effective solutions including coordination of care among multidisciplinary teams.

• Addressing educational gaps in the community oncology setting regarding initiation of care, guidance on the patient transition from academic to community setting, and assessment and management of adverse events in patients receiving BCMA BsAbs (i.e. CRS, ICANS, infection).

• Education on less frequently characterized BsAb AEs and management strategies.

• Understanding sequencing strategies in myeloma.

Equipping patients and their care partners with the necessary knowledge and resources for BCMA BsAb therapy.

• Understanding the comfort level of implementing BCMA BsAbs therapy management.

Examples of educational formats that will be considered under this RFP include but are not limited to:

• Creative educational initiatives with the potential for wide-reaching engagement.

• Education using online platforms with downloadable resources and reference tools for HCPs and/or patients.

• Professional medical society programs with wide reach to community oncologists caring for patients with RRMM.

• Interactive learnings, case-based learnings, workshops, tumor boards.

• Online articles, training courses, webinars.

• Social media posted & linked content.

• Videos, podcasts, infographics, animations.

Target Audience

Hematologists/oncologists, oncology nurses and nurse practitioners, physician associates, pharmacists, and any other healthcare professionals involved in the care of people with Relapsed/Refractory Multiple Myeloma.

Expected Approximate Monetary Range of Grant Applications

Individual projects requesting up to $125,000 will be considered. The funding of 2-3 proposals is anticipated.

• Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

AI Based Application Success Predictor

Direct alignment with Pfizer’s therapeutic focus areas, such as:
- Oncology
- Vaccines
- Inflammation & Immunology
- Rare diseases
Projects addressing unmet medical needs are prioritized

👉 Misalignment with Pfizer’s current RFP (Request for Proposals) is a major rejection factor

🎯 2. Clear Impact on Patient Outcomes

Pfizer strongly favors proposals that demonstrate:

Improved patient care or clinical outcomes
Real-world applicability (not purely theoretical research)
Measurable endpoints (e.g., survival, quality of life, adherence)

👉 Compared to academic grants, practical impact is more heavily weighted

🧪 3. Robust Study Design & Methodology

Successful applications typically include:

Well-defined study protocols
Appropriate statistical plans
Feasible recruitment strategies

👉 Weak methodology is one of the most common rejection reasons

👩‍⚕️ 4. Investigator Credentials & Track Record

Proven publication record in the relevant field
Prior clinical research experience
Institutional support and infrastructure

👉 Early-career applicants can succeed, but usually with:

Strong mentorship
Clear feasibility

🏥 5. Institutional Capability

Access to:
- Patient population
- Clinical facilities
- Data management systems
Experience in conducting industry-sponsored trials

🤝 6. Independence & Transparency

For Pfizer grants (especially IIR):

Research must be investigator-initiated and independent
Clear disclosure of:
- Conflicts of interest
- Data ownership
Pfizer does not control study outcomes

💰 7. Realistic & Justified Budget

Budget must align with:
- Study scope
- Timeline
Overinflated or vague budgets reduce success chances

📑 8. Compliance with RFP Requirements

Strict adherence to:
- Proposal format
- Submission guidelines
- Required documentation

👉 Non-compliance can lead to automatic disqualification

🌍 9. Geographic & Strategic Priorities

Pfizer often prioritizes:
- Regions with high disease burden
- Projects aligned with global health strategies

⏳ 10. Feasibility & Timeline

Clearly achievable milestones
Realistic timelines
Defined deliverables

📊 Summary: Key Predictors (Ranked)

Highest impact factors:

Alignment with Pfizer RFP & therapeutic area
Patient-centered impact
Strong methodology

Moderate predictors:
4. Investigator track record
5. Institutional capability
6. Feasibility

Supporting factors:
7. Budget clarity
8. Compliance
9. Independence & transparency

💡 Insider Insight

Unlike Horizon Europe or NIH-type grants:

👉 Pfizer funding is more application-driven than theory-driven
👉 “Will this improve patient care soon?” is the central evaluation lens

Specialties

Cancer

Hematology

Oncology

Clinical Trials

Neurosciences

Pharmaceuticals

Eligibility Requirements

• Applicant organizations to this RFP must be based in the United States

• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

• The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead’s grant coordinator).

• The project/program lead must be an employee or contractor of the requesting organization.

• For projects offering continuing education credit, the requesting organization must be accredited.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Pfizer

Sponsor Type: Corporate/Non-Profit

Address: 66 Hudson Boulevard East, New York, NY 10001-2192

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity